
IQVIA flags regulatory upheaval under Trump 2.0 as AI, FDA cuts reshape drug development
IQVIA highlighted how sweeping structural changes at key U.S. health agencies under the second Trump administration are reshaping the regulatory and policy environment for drug development, calling attention to emerging challenges and opportunities driven …